Leo Pharma looking for pediatric patients for eczema trial

In a new phase II study, Leo Pharma wants to investigate the possibility of lowering the age requirements for atopic eczema drug Adtralza.


In October last year, Leo Pharma demonstrated positive phase III data for Adtralza (tralokinumab) in atopic eczema patients aged 12–17. The company is now ostensibly trying to demonstrate that the injection treatment is safe for an even younger audience, according to a recent filing on database Clinical Trials.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs